valine has been researched along with biln 2061 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beran, RK; Bush, CO; Delaney, WE; Greenstein, AE | 1 |
| Hodges, MR; Ottosen, S; Parsley, TB; Patick, AK; Raney, AK; van der Veer, E; van Doorn, LJ; Yang, L; Zeh, K | 1 |
1 trial(s) available for valine and biln 2061
| Article | Year |
|---|---|
In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
Topics: 5' Untranslated Regions; Antiviral Agents; Carbamates; Cyclohexanols; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Macrocyclic Compounds; MicroRNAs; Molecular Targeted Therapy; Mutation; Oligonucleotides; Oligopeptides; Pyrrolidines; Quinolines; Replicon; Thiazoles; Thiophenes; Valine | 2015 |
1 other study(ies) available for valine and biln 2061
| Article | Year |
|---|---|
Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Synergism; Hepacivirus; Hepatocytes; Humans; Imidazoles; Macrocyclic Compounds; Pyrrolidines; Quinolines; Thiazoles; Time Factors; Valine; Viral Load; Virus Internalization; Virus Replication | 2013 |